Glenmark Pharmaceuticals Ltd

{"amount":2.5}

{"amount":2.5}

{"description":"Glenmark Pharmaceuticals said March 2026 quarter net profit jumped 6381.94% to Rs 301.41 crore from Rs 4.65 crore a year earlier, while sales rose 16.77%.","url":"https://www.business-standard.com/markets/capital-market-news/glenmark-pharmaceuticals-consolidated-net-profit-rises-6381-94-in-the-march-2026-quarter-126053000404_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Glenmark Pharma Q4 net profit jumped to ₹301.4 crore and FY26 PAT rose to ₹1,362 crore; board also recommended a 250% dividend and approved transfer of its nebuliser brands to GHL.","url":"https://www.cnbctv18.com/market/stocks/glenmark-pharmaceuticals-share-price-q4-net-profit-zooms-revenue-ebitda-margins-dividend-ws-l-19916004.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Glenmark Pharmaceuticals reported a strong Q3 for the period ending December 31, 2025, with net profit rising 15.9% to ₹403 crore and revenue up 15.1% to ₹3,900 crore, driven by growth in India and North America. Shares rose 2.04% to ₹2,026.10 ahead of results.","url":"https://www.cnbctv18.com/market/glenmark-pharma-q3-profit-revenue-up-15-pc-as-india-north-america-drive-growth-ws-l-19837489.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Glenmark Pharma's Monroe facility has received USFDA clearance with an Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI) status, allowing it to resume production after compliance issues since June 2023. This is expected to enhance US revenue significantly.","url":"https://www.cnbctv18.com/business/glenmark-pharma-usfda-clears-monroe-facility-vai-status-19774433.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Glenmark Pharmaceuticals reported a 72.2% increase in Q2 profit to Rs 610.43 crore, attributed to a licensing deal with AbbVie for ISB 2001. Total revenue reached Rs 6,046.87 crore, significantly up from Rs 3,433.8 crore a year earlier, reflecting strong performance in North America and Europe.","url":"https://money.rediff.com/news/market/glenmark-q2-profit-surges-72-on-abbvie-deal/36984020251114","sentiment":"Positive","domain":"Rediff Money"}

{"description":"Glenmark Pharmaceuticals Ltd. reported a significant profit increase of 72% and a revenue rise of 76.1%, reaching Rs 6,047 crore in Q2. This strong performance indicates robust growth and could positively influence investor sentiment.","url":"https://www.msn.com/en-in/money/markets/glenmark-pharma-q2-results-profit-surges-72-revenue-zooms-76/ar-AA1QrYJv?ocid=BingNewsVerp","sentiment":"Positive","domain":"NDTV Profit on MSN"}

{"description":"Glenmark Life Sciences IPO opened on July 27 at Rs 695-720. It was subscribed 44.17 times by July 29, showing strong investor interest. The listing is anticipated on BSE and NSE.","url":"https://www.firstpost.com/tag/glenmark-ipo/","sentiment":"Positive","domain":"Firstpost"}

{"description":"Glenmark Pharma has secured a $1.1 billion global licensing deal with Hengrui Pharma for the cancer drug Trastuzumab Rezetecan, allowing exclusive rights to develop and commercialize it in select markets, enhancing its oncology portfolio.","url":"https://www.goodreturns.in/news/glenmark-pharma-inks-1-1-billion-global-licensing-deal-with-hengrui-pharma-for-cancer-drug-trastuzu-1459095.html","sentiment":"Positive","domain":"Goodreturns"}